Transparency Market Research LATAM Adalimumab Market - Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023
Published Date 28-Jan-2016
61 Page Report
Buy Now
Request Sample
Press Release
Latin America Adalimumab Market to Reach US$1.18 bn by 2023; Rheumatoid Arthritis, Psoriasis Represent Largest Application Segments
Transparency Market Research State Tower, 90, State Street, Suite 700. Albany, NY 12207 United States www.transparencymarketresearch.com sales@transparencymarketresearch.com
LATAM Adalimumab Market
REPORT DESCRIPTION
LATAM Adalimumab Market - Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023 According to a new market report published by Transparency Market Research “LATAM Adalimumab Market - Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023,” the LATAM adalimumab market was valued at US$994.8 mn in 2014 and is expected to reach US$1,186.4 mn by 2023, at a CAGR of 0.4% during the forecast period from 2015 to 2023. Browse Full Report with TOC: http://www.transparencymarketresearch.com/latam-adalimumabmarket.html This report on LATAM Adalimumab market analyzes the current and future prospects of the adalimumab sales pertaining to Latin American countries. The stakeholders of this report include companies engaged in production and commercialization of adalimumab biosimilars across the globe. This report encompasses an elaborate executive summary, with a market snapshot that provides overall information of major market segments and sub-segments included in the study scope. This section also provides the overall information and data analysis of the LATAM Adalimumab market with respect to the leading market segments based on, application and major Latin American countries. The LATAM Adalimumab market has been segmented on the basis of application, and Latin American countries. The application segment has been further segmented into rheumatoid arthritis, psoriasis, Crohn’s disease, ulcerative colitis and others. The LATAM adalimumab country segment has been further categorized into Brazil, Mexico, Argentina, Colombia and Rest of LATAM. The market for each of these segment has been analyzed on the basis of adalimumab prescription for various disorders and regulatory scenario with respect to biologic drugs in respective countries. Market revenue in terms of US$ Mn for the period between 2013 and 2023 along with the compound annual growth rate (CAGR %) from 2015 to 2023 are provided for all the segments, considering 2014 as the base year.
Transparency Market Research
2
LATAM Adalimumab Market
Enquiry Before Buying: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=8716 The market overview section of this report explores market dynamics such as drivers, restraints, and opportunities that have predominant impact on the LATAM adalimumab market presently and could influence the market in future as well. The market attractiveness analysis has been provided in the market overview section in order to elucidate the intensity of competition in the market in different LATAM countries. Furthermore, pipeline analysis of the adalimumab biosimilar molecules in Phase III stage have been provided in market overview section. The market estimations for pipeline molecules are provided assuming the positive entry of these molecules in the market which will have an impact on the sustainability of the companies operating in this market. All these factors would help the market players to take strategic decisions in order to strengthen their positions and expand their shares in the LATAM market. The LATAM adalimumab analysis with respect to major LATAM countries provides the landscape for the production and marketing of adalimumab biosimilars with the introduction of favorable reimbursement policies, research expertise which paves a path for the local and foreign investments in these countries. The report also profiles major players in the adalimumab market on the basis of various attributes such as company overview, financial overview, business strategies, product portfolio, and recent developments. Some of the major players profiled in this report include AbbVie, Inc., Amgen, Inc., Mylan N.V., Novartis AG, Pfizer, Inc. and others. The LATAM Adalimumab market is segmented into the following categories: LATAM Adalimumab Market, by Application •
Rheumatoid Arthritis
•
Psoriasis
•
Crohn’s Disease
•
Ulcerative Colitis
Transparency Market Research
3
LATAM Adalimumab Market
•
Others
LATAM Adalimumab Market, by Country •
Brazil
•
Mexico
•
Argentina
•
Colombia
•
Rest of LATAM
Browse Full Press Release @ http://www.transparencymarketresearch.com/pressrelease/latam-adalimumab-market.htm
TABLE OF CONTENT
1. Preface 2. Executive Summary 2.1. LATAM Adalimumab: Market Snapshot 2.2. Comparative Analysis: LATAM Adalimumab Market, by Country, 2014 & 2023 (Value %) 2.3. LATAM Adalimumab Market Revenue, by Application, 2014 (US$ Mn) 3. Industry Analysis: LATAM Adalimumab Market 3.1. Introduction 3.2. Market Drivers 3.2.1. Driver 1: Favorable Local Regulations 3.2.2. Driver 2: Expertise in Biologic Product Research To Support Local And Foreign Investments 3.3. Market Restraints
Transparency Market Research
4
LATAM Adalimumab Market
3.3.1. Restraint 1: High Cost of R&D and Clinical trials 3.3.2. Restraint 2: Lack of reimbursement for biosimilars resulting in high out-of-pocket costs 3.4. Market Opportunities 3.4.1. Opportunity 1: LATAM, an attractive base for the biosimilar developers for their product expansion 3.5. Market Attractiveness Analysis– LATAM Adalimumab Market, by Country (2014) (value %) 3.6. Pipeline Analysis: LATAM Adalimumab Market 4. LATAM Adalimumab Market Segmentation – by Application 4.1. Introduction 4.2. LATAM Adalimumab Market Revenue, by Application 2013–2023 (US$ Mn) 4.3. LATAM Adalimumab Market Revenue for Rheumatoid Arthritis, 2013–2023, (US$ Mn) 4.4. LATAM Adalimumab Market Revenue for Psoriasis, 2013–2023, (US$ Mn) 4.5. LATAM Adalimumab Market Revenue for Crohn’s Disease, 2013–2023, (US$ Mn) 4.6. LATAM Adalimumab Market Revenue for Ulcerative Colitis, 2013–2023, (US$ Mn) 4.7. LATAM Adalimumab Market Revenue for Others, 2013–2023, (US$ Mn) 5. LATAM Adalimumab Market Segmentation – by Country 5.1. Introduction 5.2. LATAM Adalimumab Market Revenue, by Country, 2013–2023 (US$ Mn) 5.3. Brazil Adalimumab Market Revenue, 2013–2023 (US$ Mn) 5.4. Mexico Adalimumab Market Revenue, 2013–2023 (US$ Mn) 5.5. Argentina Adalimumab Market Revenue, 2013-2023 (US$ Mn) 5.6. Colombia Adalimumab Market Revenue, 2013–2023 (US$ Mn) 5.7. Rest of LATAM Adalimumab Market Revenue, 2013-2023 (US$ Mn) 6. Recommendations 7. Company Profiles
Transparency Market Research
5
LATAM Adalimumab Market
7.1. AbbVie, Inc. 7.2. Amgen, Inc. 7.3. Boehringer Ingelheim GmbH 7.4. Eisai Co., Ltd. 7.5. Mylan N.V. 7.6. Novartis AG 7.7. Pfizer, Inc.
About Us Transparency Market Research (TMR) is a U.S.-based provider of syndicated research, customized research, and consulting services. TMR’s global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical
forecasts,
competitive
landscape,
detailed
segmentation,
key
trends,
recommendations.
Contact
Transparency Market Research 90 State Street, Suite 700, Albany NY - 12207 United States Tel: +1-518-618-1030 USA - Canada Toll Free 866-552-3453 Email: sales@transparencymarketresearch.com Website: http://www.transparencymarketresearch.com/ Browse Market Research Blog : https://marketsresearchindustry.wordpress.com/
Transparency Market Research
6
and
strategic